Results of Operations and Financial Condition . On August 13, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and six months ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, fi…

Results of Operations and Financial Condition . On May 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three months ended March, 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial p…

Results of Operations and Financial Condition . On March 19, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s pe…

in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific r…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s co…

Results of Operations and Financial Condition. On November 13, 2025, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and nine months ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performa…

Entry into a Material Definitive Agreement. On November 6, 2025 (the “ Closing Date ”), Biofrontera Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ APA ”) with Pelthos Therapeutics Inc. (the “ Purchaser ”), an unaffiliated party, providing for the sale of all of the assets relating to the Company’s product, Xepi® (ozenoxacin) cream (the “ Transaction ”). The Transaction was completed on the Closing Date. Capitalized terms used below that are not defined herein shall hav…

Completion of Acquisition or Disposition of Assets. The information contained above in

The Series C Preferred Stock are being issued and, upon conversion, the Common Stock issuable upon conversion of the Series C Preferred Stock will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Entry into a Material Definitive Agreement. Closing of Strategic Transaction with Biofrontera AG On October 20, 2025, Biofrontera Inc. (the “ Company ”) entered into i) an Asset Purchase Agreement (the “Transfer Agreement”) and ii) an Earnout Agreement (the “Earnout Agreement”, and collectively with the Transfer Agreement, the “ Agreements ”), with its former parent company Biofrontera AG and its subsidiaries, pursuant to which the Company finalized the agreements to acquire all rights in the…

Other Information Private Placement of Series C Preferred Stock As previously disclosed in the July 8-K, on June 27, 2025, as a condition precedent for the Strategic Transaction, the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Series C Preferred Offering ”), up to 11,000 shares (the “ Series C Preferred Shares ”) of…

Completion of Acquisition or Disposition of Assets. The information contained in

Results of Operations and Financial Condition. On August 13, 2025, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and six months ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, fin…

Chief Commercial Officer — George Jones: George Jones was hired as the Chief Commercial Officer from an external company.

Material Modification to Rights of Security Holders The information in response to

Entry into a Material Definitive Agreement. Strategic Transaction with Biofrontera AG On June 30, 2025, Biofrontera Inc. (the “ Company ”) signed an agreement (the “ Agreement ”) with its former parent company Biofrontera AG and its subsidiaries pursuant to which the Company acquired all rights in the United States (the “ U.S. Rights ”) to Ameluz ® and RhodoLED ® (the “ Strategic Transaction ”). Pursuant to the Agreement, the Company will now pay a royalty of 12% in years where Ameluz ® reven…

The Series C Preferred Stock and Series D Preferred Stock are being issued and, upon conversion, the Common Stock issuable upon conversion of the Series C Preferred Stock and Series D Preferred Stock will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 21, 2025, Biofrontera Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended March 31, 2025 was $469,000, the Company is no longer in compliance with the continued listing requirement under Nasdaq Listing Rule…

Results of Operations and Financial Condition. On May 15, 2025, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three months ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial pos…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 8, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common s…

Changes in Registrant’s Certifying Accountant. Based on information provided by Marcum LLP (“Marcum”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. On April 17, 2025, Marcum resigned as the independent registered public accounting firm of Biofrontera Inc. (the “Company”) and, with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for t…

Results of Operations and Financial Condition. On March 21, 2025, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s per…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Unregistered Sale of Equity Securities The information set forth under

Entry into a Material Definitive Agreement. On November 21, 2024, Biofrontera Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with its principal stockholders (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of $4,200,000 in aggregate principal amount of the Company’s 10.0% Senior Secured Convertible Notes due November 22, 2027 (the “ Notes ”). The closing of the Priv…